Comparing the current results to its competitors, Certara Inc reported Revenue decrease in the 2 quarter 2026 year on year by -10.81 %, faster than the overall decrease of Certara Inc 's competitors by -7.58 %, recorded in the same quarter.
Certara Inc 's Comment on Competition and Industry Peers
The biosimulation products and related services market in the biopharmaceutical industry is competitive and fragmented, with participants varying in size, capabilities, and scope. Some industry players continue to rely on traditional research methods rather than utilizing modeling, simulation, artificial intelligence, dataflow, and analytics platforms. Key competitive factors include model functionality and quality, the range of molecular types and therapeutic areas supported, regulatory acceptance, ease of use, drug development experience, brand reputation, cost, and integration capabilities. The company competes favorably based on these factors and faces significant barriers to new entrants due to the required investment in validated models, software, and model-informed drug development (MIDD) expertise. Competitors in the biosimulation software market include Mathworks, Dassault Systemes, Ansys, Simulations Plus, NONMEM (a division of ICON), as well as open-source solutions such as R and PK-Sim, and internally developed software by biopharmaceutical companies.
September 18, 2024
In the ever-evolving field of oncology, the quest for innovative therapies that can effectively target cancer has led to exciting collaborations aimed at optimizing drug development. A notable recent partnership is between Certara, a knowledge-based drug development company specializing in biosimulation, and Ichnos Glenmark Innovation (IGI), a biotechnology company focused on advancing novel cancer treatments. Their collaboration marks a significant leap toward the first-in-class cancer drug, ISB 2001, offering new hope in the fight against cancer.Certara s expertise in predictive modeling and biosimulation has positioned the company at the forefront of precision medicine. Through their innovative methodolog...
June 17, 2024
Certara Unveils Next Generation AI Writing Software and Reports Revenue Increase in Q1 2024Certara, a leading provider of drug development and regulatory science software, announced the launch of its advanced CoAuthor regulatory writing software, designed specifically for medical writers. The new generation software is set to revolutionize the field by leveraging generative AI technology to enhance the efficiency and accuracy of regulatory writing processes.The CoAuthor software offers a range of innovative features that will undoubtedly benefit medical writers, enabling them to produce high-quality, compliant, and scientifically robust documents. By harnessing the power of generative AI, CoAuthor streamline...
Simulations Plus Inc operates in the pharmaceutical and biotechnology industries, providing simulation software and consulting services to assist in drug development processes.
Schrodinger Inc is a computational drug discovery company that utilizes physics-based solutions to accelerate the discovery and development of new drugs. Their business model involves providing software and services to pharmaceutical and biotechnology companies, enabling them to optimize and streamline their drug discovery processes. By leveraging their unique expertise in computational chemistry and molecular modeling, Schrodinger aims to empower their clients in the pursuit of efficient and effective drug development.
Icon Plc is a leading provider of clinical research services, specializing in the design and management of clinical trials for pharmaceutical and biotechnology companies. Their business model focuses on offering a comprehensive range of services, including study design, data management, regulatory support, and statistical analysis, to support the development of new drugs and medical devices. Icon Plc's success lies in its ability to provide customized solutions to its clients, efficiently navigate the regulatory landscape, and consistently deliver high-quality and timely results.
Sources:
Certara Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Certara Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
